OR WAIT null SECS
Click here to read the articles and view the interactive digital edition
Why driving results from such strategies—amid industry disruption—will be critical to success.
The advantages and challenges associated with structuring a patient assistance program as a non-profit foundation.
An exploration into how flawed incentives and contractual loopholes between manufacturers and pharmacy benefit managers played their part.
July 21, 2025
In the final part of his Pharma Commerce video interview, Sean O’Hearen, founder and principal consultant at 1st Line Partners, offers communication strategies for staying confident in genuine pharmaceuticals while also remaining vigilant against counterfeit threats.
The acquisition merges eBlu’s automation platform with Knipper’s nationwide distribution network, streamlining benefit verification, prior authorization, and patient onboarding while reducing administrative burdens for specialty providers.
Industry stakeholders suggest how pharmaceutical companies can proactively plan for the potential implementation of a Most Favored Nation (MFN) pricing model.
In the final part of his Pharma Commerce video interview, Murray Aitken, executive director, IQVIA Institute for Human Data Science, details how he sees the competitive landscape evolving
July 18, 2025
In the fourth part of this roundtable discussion, a panel of subject matter experts dive into data exchange challenges relating to the Drug Supply Chain Security Act.
The study reveals that resilience varies significantly by race, education, income, and insurance status, highlighting the role of social determinants and systemic inequities in shaping health outcomes.
In the fourth part of his Pharma Commerce video interview, Sean O’Hearen, founder and principal consultant at 1st Line Partners, describes the prominence of underreporting falsified medicines.
July 17, 2025
In the fourth part of his Pharma Commerce video interview, Murray Aitken, executive director, IQVIA Institute for Human Data Science, outlines what he anticipates for the biosimilar adoption curve in key markets moving forward.
Pharma prepares for looming tariffs, as the US president signals a phased increase starting Aug. 1, but the official starting tax rate is yet to be determined.